Biodel To Report Results Of VIAject™ Pivotal Phase III Clinical Trials At EASD Conference

 05.09.2008 06:17   medicalnewstoday.com

Biodel Inc. (Nasdaq: BIOD) announced that it will report results of its two pivotal Phase III clinical trials of VIAject™ in patients with Type 1 and Type 2 diabetes next week at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome. Two posters summarizing these results, #677 by Flacke et al.

World Diabetes